Elanco Animal Health Inc's Chief Executive Officer, Jeffrey N. Simmons, has acquired 120.04 deferred stock units as of October 16, 2026. This acquisition is significant as it underscores the company's commitment to aligning executive compensation with shareholder interests, a trend increasingly observed in the pharmaceutical preparations industry.
Elanco Animal Health Inc, identified by the Central Index Key 0001739104, operates within the pharmaceutical preparations sector (SIC: 2834). The company is publicly traded on the New York Stock Exchange under the ticker symbol ELAN. Elanco is known for its focus on animal health, providing products and services to enhance the health and well-being of livestock and pets.
According to the recent SEC filing (accession number 0001479079-26-000047), Simmons's transaction involved the acquisition of deferred stock units valued at $23.55 per share. The filing notes, "Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent." Following this transaction, Simmons now holds a total of 25,619.32 shares in Elanco.
This development may impact various stakeholders, including shareholders and employees, as it reflects a broader trend in corporate governance where executive compensation is increasingly tied to company performance. By acquiring these units, Simmons demonstrates confidence in Elanco's future and aligns his financial interests with those of the shareholders.
The filing does not say what happens next regarding further transactions or corporate actions related to this acquisition.